There will be no increase in the maximum amount of the annual premium for the public drug insurance plan (RPAM) this year, announced Minister Christian Dubé.
This amount therefore remains fixed at $710 until June 30, 2023.
“This is excellent news for those insured under the public prescription drug insurance plan, who will be able to benefit from less financial pressure than expected, in a difficult context of marked inflation,” declared the Minister of Health. Health and Social Services, Christian Dubé.
The savings generated by negotiating listing agreements with manufacturers made this freeze possible, the government said.
“The favorable pricing terms and discounts provided by these agreements mitigate the cost associated with new drug coverage,” reads a press release.
“More specifically, the switch to biosimilar products, which are significantly less expensive than the reference biological products (innovative products), has made it possible to create sufficient leeway making it possible to freeze the insurance premium as well as the parameters of the contribution to the ‘purchase of the insured persons of the public plan’, we read then.
In addition to freezing this maximum amount, other contribution parameters also remain unchanged from July 1, 2021, in particular the amount of the deductible, set at $22.25, and the co-insurance proportion, set at 35%, of same as the monthly contribution of certain people aged 65 and over.